For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Gaucher disease is an inherited disorder that affects many of the body's organs and tissues. The signs and symptoms of this condition vary widely among affected individuals.
LPI (LP Information)' newest research report, the "Gaucher Disease Industry Forecast" looks at past sales and reviews total world Gaucher Disease sales in 2022, providing a comprehensive analysis by region and market sector of projected Gaucher Disease sales for 2023 through 2029. With Gaucher Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gaucher Disease industry.
This Insight Report provides a comprehensive analysis of the global Gaucher Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gaucher Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Gaucher Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gaucher Disease and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gaucher Disease.
The global Gaucher Disease market size is projected to grow from US$ 1181.7 million in 2022 to US$ 2163.7 million in 2029; it is expected to grow at a CAGR of 2163.7 from 2023 to 2029.
Global Gaucher Disease key players include Sanofi, Takeda, Actelion Pharma, etc. Global top three manufacturers hold a share over 95%.
Europe is the largest market, with a share about 55%, followed by United States and Others, both have a share about 45 percent.
In terms of product, Enzyme Replacement Therapy is the largest segment, with a share over 90%. And in terms of application, the largest application is Non-neuronopathic Gaucher Disease, followed by Neuronopathic Gaucher Disease.
This report presents a comprehensive overview, market shares, and growth opportunities of Gaucher Disease market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Enzyme Replacement Therapy
- Substrate Reduction Therapy
Segmentation by application
- Non-neuronopathic Gaucher Disease
- Neuronopathic Gaucher Disease
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Sanofi
- Takeda
- Actelion Pharma
- Pfizer (Protalix)
- ISU ABXIS
Key Questions Addressed in this Report
What is the 10-year outlook for the global Gaucher Disease market?
What factors are driving Gaucher Disease market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Gaucher Disease market opportunities vary by end market size?
How does Gaucher Disease break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?